Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.25 USD
Change Today -0.165 / -3.05%
Volume 4.2M
PDLI On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

pdl biopharma inc (PDLI) Snapshot

Open
$5.29
Previous Close
$5.42
Day High
$5.29
Day Low
$4.93
52 Week High
09/3/14 - $10.19
52 Week Low
08/24/15 - $4.58
Market Cap
861.9M
Average Volume 10 Days
2.9M
EPS TTM
$1.90
Shares Outstanding
164.2M
EX-Date
09/2/15
P/E TM
2.8x
Dividend
$0.60
Dividend Yield
11.43%
Current Stock Chart for PDL BIOPHARMA INC (PDLI)

Related News

No related news articles were found.

pdl biopharma inc (PDLI) Related Businessweek News

No Related Businessweek News Found

pdl biopharma inc (PDLI) Details

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. has license agreements with various biotechnology and pharmaceutical companies, as well as acquires royalty and other assets. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

10 Employees
Last Reported Date: 08/5/15
Founded in 1986

pdl biopharma inc (PDLI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $716.1K
Chief Financial Officer and Vice President
Total Annual Compensation: $405.6K
Vice President, General Counsel and Secretary
Total Annual Compensation: $415.8K
Vice President of Business Development
Total Annual Compensation: $343.1K
Compensation as of Fiscal Year 2014.

pdl biopharma inc (PDLI) Key Developments

PDL BioPharma, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

PDL BioPharma, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total Revenue was $138.07 million against $162.75 million a year ago. The decrease in revenue was primarily driven by the decrease in the Depomed royalty rights cash proceeds related to the Salix Pharmaceuticals Ltd. (recently acquired by Valeant Pharmaceuticals International, Inc.) excess supply of Glumetza at the wholesaler inventory levels, decreased interest revenues due to the early payoff of the AxoGen and Durata notes receivables, and decreased Actemra royalties as a result of the conclusion of the Actemra license agreement, partially offset by increased royalties from sales of Perjeta, Xolair, Kadcyla, Herceptin, and Tysabri. Operating income was $130.64 million against $155.83 million a year ago. Income before income taxes was $123.56 million against $146.06 million a year ago. Net income was $78.26 million or $0.47 diluted per share against $92.06 million or $0.52 diluted per share a year ago. For the six months, the company reported total Revenue was $244.69 million against $231.09 million a year ago. Operating income was $272.68 million against $288.05 million a year ago. Income before income taxes was $257.07 million against $261.66 million a year ago. Net income was $162.76 million or $0.97 diluted per share against $164.94 million or $0.94 diluted per share a year ago. The decrease in net income was primarily driven by the decrease in the Depomed royalty rights cash proceeds. Net cash provided by operating activities was $155.900 million against $146.153 million a year ago.

PDL BioPharma, Inc. to Report Q2, 2015 Results on Aug 05, 2015

PDL BioPharma, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 05, 2015

PDL BioPharma, Inc., Q2 2015 Earnings Call, Aug 05, 2015

PDL BioPharma, Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDLI:US $5.25 USD -0.165

PDLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €10.30 EUR +0.16
BioInvent International AB kr2.76 SEK -0.01
Genmab A/S kr603.00 DKK +26.00
XOMA Corp $0.84 USD +0.0598
View Industry Companies
 

Industry Analysis

PDLI

Industry Average

Valuation PDLI Industry Range
Price/Earnings 2.9x
Price/Sales 1.8x
Price/Book 1.7x
Price/Cash Flow 2.8x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDL BIOPHARMA INC, please visit www.pdl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.